120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
C 反应蛋白和纤维蛋白原联合预测脑静脉窦血栓形成患者颅内高压的作用
Authors Xu Y, Yan J, Lu M, Huang Z, Ni J, Zhang X
Received 7 August 2025
Accepted for publication 27 January 2026
Published 7 February 2026 Volume 2026:19 554496
DOI https://doi.org/10.2147/JIR.S554496
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Prof. Dr. Dharmappa Krishnappa
Yingying Xu,1,* Jiahui Yan,1,* Manli Lu,1 Zhichao Huang,1 Jianqiang Ni,2 Xia Zhang1
1Department of Neurology and Clinical Research Center of Neurological Disease, the Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People’s Republic of China; 2Department of Neurology, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xia Zhang, Department of Neurology and Clinical Research Center of Neurological Disease, the Second Affiliated Hospital of Soochow University, No. 1055, Sanxiang Road, Suzhou, Jiangsu, 215004, People’s Republic of China, Tel +86 512 67784786, Email stefence1025@163.com Jianqiang Ni, Department of Neurology, the First Affiliated Hospital of Soochow University, No. 899, Pinghai Road, Suzhou, Jiangsu, 215031, People’s Republic of China, Tel +86 512 67780327, Email njq@suda.edu.cn
Purpose: Intracranial hypertension is the most common symptom of cerebral venous sinus thrombosis. Recent studies have indicated that both the coagulation and inflammation systems play roles in the occurrence and development of cerebral venous sinus thrombosis. Therefore, this study aimed to explore the individual and combined effects of coagulation-related biomarker [fibrinogen (FIB)] and inflammation-related biomarker [C-reactive Protein (CRP)] in predicting intracranial hypertension.
Patients and Methods: We retrospectively and consecutively included 157 cerebral venous sinus thrombosis patients, who were divided into four groups according to the cut-offs of CRP and FIB by the receiver operating characteristics curves: low CRP low FIB, high CRP low FIB, low CRP high FIB and high CRP high FIB. Logistic regression models were used to compute the odds ratios and 95% confidence intervals for intracranial hypertension across the four subgroups.
Results: Cerebral venous sinus thrombosis patients with intracranial hypertension had much higher CRP and FIB levels than those without intracranial hypertension did (all P< 0.05). After adjusted by gender, age, modified Rankin scale, duration, headache, seizure, smoking, history of thrombosis and other risk factors, white blood cell, systemic immune-inflammation index and estimated glomerular filtration rate, patients in high CRP high FIB group were 5.286 (95% CI: 2.04– 13.701, P=0.001) times more frequent to experience intracranial hypertension than those in low CRP low FIB group did. The addition of CRP and FIB to the basic model significantly improved discriminatory power for intracranial hypertension, as area under the curve increased from 0.692 (95% CI: 0.609– 0.775, P< 0.001) to 0.767 (95% CI: 0.692– 0.843, P< 0.001).
Conclusion: Higher levels of both CRP and FIB are associated with an increased risk of intracranial hypertension following cerebral venous sinus thrombosis. The combination of CRP and FIB has a better predictive ability for intracranial hypertension in patients with cerebral venous sinus thrombosis than either CRP or FIB alone.
Keywords: inflammation biomarker, coagulation factor, cerebrovascular disease, joint effect
1Department of Neurology and Clinical Research Center of Neurological Disease, the Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People’s Republic of China; 2Department of Neurology, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xia Zhang, Department of Neurology and Clinical Research Center of Neurological Disease, the Second Affiliated Hospital of Soochow University, No. 1055, Sanxiang Road, Suzhou, Jiangsu, 215004, People’s Republic of China, Tel +86 512 67784786, Email stefence1025@163.com Jianqiang Ni, Department of Neurology, the First Affiliated Hospital of Soochow University, No. 899, Pinghai Road, Suzhou, Jiangsu, 215031, People’s Republic of China, Tel +86 512 67780327, Email njq@suda.edu.cn
Purpose: Intracranial hypertension is the most common symptom of cerebral venous sinus thrombosis. Recent studies have indicated that both the coagulation and inflammation systems play roles in the occurrence and development of cerebral venous sinus thrombosis. Therefore, this study aimed to explore the individual and combined effects of coagulation-related biomarker [fibrinogen (FIB)] and inflammation-related biomarker [C-reactive Protein (CRP)] in predicting intracranial hypertension.
Patients and Methods: We retrospectively and consecutively included 157 cerebral venous sinus thrombosis patients, who were divided into four groups according to the cut-offs of CRP and FIB by the receiver operating characteristics curves: low CRP low FIB, high CRP low FIB, low CRP high FIB and high CRP high FIB. Logistic regression models were used to compute the odds ratios and 95% confidence intervals for intracranial hypertension across the four subgroups.
Results: Cerebral venous sinus thrombosis patients with intracranial hypertension had much higher CRP and FIB levels than those without intracranial hypertension did (all P< 0.05). After adjusted by gender, age, modified Rankin scale, duration, headache, seizure, smoking, history of thrombosis and other risk factors, white blood cell, systemic immune-inflammation index and estimated glomerular filtration rate, patients in high CRP high FIB group were 5.286 (95% CI: 2.04– 13.701, P=0.001) times more frequent to experience intracranial hypertension than those in low CRP low FIB group did. The addition of CRP and FIB to the basic model significantly improved discriminatory power for intracranial hypertension, as area under the curve increased from 0.692 (95% CI: 0.609– 0.775, P< 0.001) to 0.767 (95% CI: 0.692– 0.843, P< 0.001).
Conclusion: Higher levels of both CRP and FIB are associated with an increased risk of intracranial hypertension following cerebral venous sinus thrombosis. The combination of CRP and FIB has a better predictive ability for intracranial hypertension in patients with cerebral venous sinus thrombosis than either CRP or FIB alone.
Keywords: inflammation biomarker, coagulation factor, cerebrovascular disease, joint effect